Florence Loiseau1, Anne Dekeyne, Mark J Millan. 1. Department of Psychopharmacology, Institut de Recherches Servier, 125 Chemin de ronde, 78290, Croissy-sur-Seine, Paris, France.
Abstract
RATIONALE: 5-HT6 receptor antagonists improve cognitive processes in rodents. However, their site(s) of action remains unexplored and their influence upon social memory has been little investigated. OBJECTIVES: We examined the influence of 5-HT6 receptor ligands upon social memory in rats by use of systemic or local administration into the frontal cortex (FCX), striatum, or nucleus basalis magnocellularis (NBM). MATERIALS AND METHODS: The social recognition test is based upon the ability of an adult rat to recognize a younger conspecific during the second of two 5-min sessions. In a procedure without an inter-session interval, the actions of drugs alone and the ability to reverse "amnesia" induced by the muscarinic antagonist, scopolamine (1.25 mg/kg, s.c.), were examined. The potential promnesic effect of drugs was also investigated in another procedure where a spontaneous deficit of recognition was induced by a 120-min inter-session interval. RESULTS: The 5-HT6 receptor agonist, WAY-181187 (10.0 mg/kg, i.p.), significantly impaired social recognition. This effect was abolished by the 5-HT6 receptor antagonists, SB-271046 (20.0 mg/kg, i.p.) and SB-258585 (10.0 mg/kg, i.p.). These agents also abolished scopolamine-induced amnesia (10.0 and 2.5 mg/kg, i.p., respectively) and reversed the delay-induced deficit (10.0-20.0 and 2.5-10.0 mg/kg, i.p., respectively). WAY-181187 into the FCX significantly impaired social recognition (0.16-0.63 microg/side). Conversely, SB-271046 into the FCX (2.5-5.0 microg/side), but neither into the striatum nor the NBM, significantly reversed spontaneous deficit. CONCLUSION: These results indicate that 5-HT6 receptors modulate social recognition by actions in the FCX and underpin their pertinence as targets for the treatment of psychiatric disorders in which cognitive function is compromised.
RATIONALE: 5-HT6 receptor antagonists improve cognitive processes in rodents. However, their site(s) of action remains unexplored and their influence upon social memory has been little investigated. OBJECTIVES: We examined the influence of 5-HT6 receptor ligands upon social memory in rats by use of systemic or local administration into the frontal cortex (FCX), striatum, or nucleus basalis magnocellularis (NBM). MATERIALS AND METHODS: The social recognition test is based upon the ability of an adult rat to recognize a younger conspecific during the second of two 5-min sessions. In a procedure without an inter-session interval, the actions of drugs alone and the ability to reverse "amnesia" induced by the muscarinic antagonist, scopolamine (1.25 mg/kg, s.c.), were examined. The potential promnesic effect of drugs was also investigated in another procedure where a spontaneous deficit of recognition was induced by a 120-min inter-session interval. RESULTS: The 5-HT6 receptor agonist, WAY-181187 (10.0 mg/kg, i.p.), significantly impaired social recognition. This effect was abolished by the 5-HT6 receptor antagonists, SB-271046 (20.0 mg/kg, i.p.) and SB-258585 (10.0 mg/kg, i.p.). These agents also abolished scopolamine-induced amnesia (10.0 and 2.5 mg/kg, i.p., respectively) and reversed the delay-induced deficit (10.0-20.0 and 2.5-10.0 mg/kg, i.p., respectively). WAY-181187 into the FCX significantly impaired social recognition (0.16-0.63 microg/side). Conversely, SB-271046 into the FCX (2.5-5.0 microg/side), but neither into the striatum nor the NBM, significantly reversed spontaneous deficit. CONCLUSION: These results indicate that 5-HT6 receptors modulate social recognition by actions in the FCX and underpin their pertinence as targets for the treatment of psychiatric disorders in which cognitive function is compromised.
Authors: D R Weinberger; M F Egan; A Bertolino; J H Callicott; V S Mattay; B K Lipska; K F Berman; T E Goldberg Journal: Biol Psychiatry Date: 2001-12-01 Impact factor: 13.382
Authors: Mark D Lindner; Donald B Hodges; John B Hogan; Anitra F Orie; Jason A Corsa; Donna M Barten; Craig Polson; Barbara J Robertson; Valerie L Guss; Kevin W Gillman; John E Starrett; Valentin K Gribkoff Journal: J Pharmacol Exp Ther Date: 2003-09-15 Impact factor: 4.030
Authors: Kwang-Hyuk Lee; Wendy H Brown; Paul N Egleston; Russell D J Green; Tom F D Farrow; Michael D Hunter; Randolph W Parks; Iain D Wilkinson; Sean A Spence; Peter W R Woodruff Journal: Am J Psychiatry Date: 2006-11 Impact factor: 18.112
Authors: Andrew G Foley; Keith J Murphy; Warren D Hirst; Helen C Gallagher; Jim J Hagan; Neil Upton; Frank S Walsh; Ciaran M Regan Journal: Neuropsychopharmacology Date: 2004-01 Impact factor: 7.853
Authors: M Ruat; E Traiffort; J M Arrang; J Tardivel-Lacombe; J Diaz; R Leurs; J C Schwartz Journal: Biochem Biophys Res Commun Date: 1993-05-28 Impact factor: 3.575
Authors: Paweł Zajdel; Krzysztof Marciniec; Grzegorz Satała; Vittorio Canale; Tomasz Kos; Anna Partyka; Magdalena Jastrzębska-Więsek; Anna Wesołowska; Agnieszka Basińska-Ziobroń; Jacek Wójcikowski; Władysława A Daniel; Andrzej J Bojarski; Piotr Popik Journal: ACS Med Chem Lett Date: 2016-04-07 Impact factor: 4.345
Authors: Nagi Idris; Jo Neill; Ben Grayson; Benny Bang-Andersen; Louise M Witten; Lise Tøttrup Brennum; Jørn Arnt Journal: Psychopharmacology (Berl) Date: 2009-10-23 Impact factor: 4.530